Drug Meeting Ground

Forums of Exchange

Uwe Schoenbeck, Chief Scientific Officer External R&D Innovation (ERDI), Pfizer Worldwide R&D
- Evolving Models of Innovation for Breakthrough Medicines: New Concepts at Pfizer

Raphael Hofstein, President & CEO, MaRs Innovation
- MaRs Innovation's role in building the bridge over the valley of death
Michelle Browner, CEO, Enlight Biosciences
- Enlight Biosciences: Collaborative Venture Creation
Aled Edwards, CEO, Structural Genomics Consortium
- Open access: From target to POC

Special Tribute
- Jean-Claude Gavrel
  - Innovation: Needs and Challenges
Panelists
- Moderator: Lloyd Segal, Managing Partner, Persistence Capital Partner
- Janelle Anderson, Director Business Integration, Merck
- Cédric Bisson, Venture Partner, Teralys Capital
- Daniel Böck, Director, Business Development, GlaxoSmithKline
- Elizabeth Douville, General Partner, AmorChem
- Daniel Hétu, Managing Director, Lumira Capital
- Jean-François Leprince, Managing Partner,CTI Life Sciences Fund
- Luc Marengère, Managing Partner, TVM Capital
- Paul K. Owens, Senior Director, Chorus and Global External R&D, Lilly Corporate Center
- Laurence Rulleau, Vice-President Business Development, Univalor
Closing statement
- Christyne Tremblay, Deputy Minister, MDEIE
  - Life Sciences: Towards a new business model